Kotak noted that Cognizant’s deal mix has become more balanced between cost optimisation and innovation-led engagements, a ...
Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback